All News
Infectious Mortality in Autoimmune Rheumatic Disorders
Infectious conditions are a significant cause of mortality in autoimmune rheumatic diseases (ARD). Among patients hospitalized with an infection, we compared in-hospital and long-term (3-year) mortality between those with and without ARD.
Small-molecule Drugs to Treat Systemic Lupus Erythematosus
A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs.
Interferons and Lupus Subsets
EurekAlert!
In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans.
Read Article
Retrospective cohort study compared 5825 #AS pts vs 28,356 matched controls; showed an increased risk of pulmonary embolism w/ AS; not present pre-Dx ((0.4% vs 0.2%), but incr post-AS Dx (PE IR 11.6 vs 6.8/10KPY: adj HR 1.70;; p<0.001) https://t.co/Tsd77iUsjC https://t.co/sd6wbtuaqw
Dr. John Cush RheumNow ( View Tweet)
In animal models, IL-22 may have protective effects against pulm fibrosis. Study of 66 new #RA pts (1/2 w/ ILD) & 14 controls. Serum IL-22 was signif lower in RA-ILD; and was inversely correlated with the severity of RA-ILD https://t.co/Rmr5N2JznH https://t.co/OZ1ZrgGXC3
Links:
Dr. John Cush RheumNow ( View Tweet)
K Kuhn et al: Altered tryptophan catabolism by microbiome may contribute to inflammatory arthritis. Tryptophan increases indole leading to ncreases in serum IL-6, TNF, and IL-1β; splenic RORγt+CD4+ T cells, & IL-23 and IL-17 production https://t.co/Bqm5ecvGR5 https://t.co/O1jCSqFICr
Dr. John Cush RheumNow ( View Tweet)
The EMAs CHMP has recommended for approval Two biosimilars, Tofidence (tocilizumab) and Wezenla (ustekinumab) https://t.co/mREclYdeCk https://t.co/zQX00Ys8oH
Dr. John Cush RheumNow ( View Tweet)
MGH study compared 1148 acute CPPD vs 3730 controls (mean 73 yrs) found 2 fold more fractures (mostly wrist); 11.7 vs 5.5/1000 PYs (HR 1.8) in pseudogout pts (also had more steroids & OP) https://t.co/HhCV6fYubF https://t.co/3bcbvSzzPo
Dr. John Cush RheumNow ( View Tweet)
Substitute Measures of Inflammation (many dervied from the CBC)
https://t.co/rYBqrNH8Zo https://t.co/Fa1mC17ErJ
Dr. John Cush RheumNow ( View Tweet)
RECIPE Study: Non-opioid Analgesics following Total Hip Arthroplasty
Patients undergoing total hip arthroplasty using a combo of paracetamol, ibuprofen, + dexamethasone, had optimal responses with the lowest morphine consumption, & fewer adverse events.
https://t.co/PXmPGscwu3 https://t.co/2Lse0gNx70
Dr. John Cush RheumNow ( View Tweet)
RISE study of 700 Pegloticase users (14 mos F/U) found 18% on immunosuppressive (MTX, MMF, LEF), these had signif less PEG D/C (HR 0.52-0.69). Immunosuppressives not assoc w/ more lab abnormalities https://t.co/4ytot7HOMh https://t.co/0wrjvnZur3
Dr. John Cush RheumNow ( View Tweet)
PI states risk of GI Perforations (GIP) incr w/ IL-6i (1.1--2.6/1000PYs) & JAKi (~1-2/1000PY) . French Insurance pop. study of ~40K pts on JAKi or adalimumab found NO no signif difference betw JAK v ADA (IR: 2.1 vs 1.1/1000PYs; p=0.65). https://t.co/YlxiBOhNFj https://t.co/A5hMbWDXeV
Dr. John Cush RheumNow ( View Tweet)
NEJM: evolution of pyoderma gangrenosum skin lesions https://t.co/wE9pAZZs9L https://t.co/jTijcCvpfI
Links:
Dr. John Cush RheumNow ( View Tweet)
Who is confused about what to do for #GI symptoms in #scleroderma? @TimKanieckiMD does a masterful breakdown of gut involvement for @jhrheumatology rounds. You can read further in: https://t.co/xw6EElGIWl
@ZsuzsannaM55365 would be proud!
#MentoredResearchProjects
#dysmotility https://t.co/yLVD7Vo1SJ
Links:
Johns Hopkins Rheumatology Fellows JHRheumFellows ( View Tweet)
10 Lupus Tips on May 10 (World Lupus Day) by @LupusMore
https://t.co/mON5ZyTpUE
#lupus #SLE #LupusAwarenessMonth
Links:
Donald Thomas, MD lupuscyclopedia ( View Tweet)
✅ Holistic #Lupus Management in 2024 👍 #LupusAwarenessMonth https://t.co/RY6AcHS9WQ
Laurent ARNAUD Lupusreference ( View Tweet)
"On being a physician" - a White Coat Ceremony address by Dr. John F. Fischer from the Medical College of Georgia 2024 https://t.co/tBlT6DEddU via @YouTube
Dr. John Cush RheumNow ( View Tweet)
Long term F/U of T2T in BeST (early RA 153) & IMPROVED (UA 282) pts 12 & 20 yrs after, the majority of RA & UA pts were in DAS remission (91% LDAS, 68% remission), & w/ limited functional disability (mean HAQ 0.6-0.8). Xray progression was mild https://t.co/J9AfSPhWoK https://t.co/SrVJywF2JI
Dr. John Cush RheumNow ( View Tweet)
Study of 187 Oligoarticular JIA pts - Remission was achieved w/ DMARDs in 65.8%; predictors of nonresponse (DMARD resistance) - Elevated CRP (> 1.1 mg/dL' OR 1.3) & and high JADAS-71 at Dx (> 15.8; OR 1.7) https://t.co/oPajnplXUL https://t.co/TnrknASCzb
Dr. John Cush RheumNow ( View Tweet)
Does Good Sleep Prevent Osteoporosis?
https://t.co/hA9O1UIItx https://t.co/SoEX6p4xNH
Dr. John Cush RheumNow ( View Tweet)
